Charles Schwab Investment Management Inc. Raises Position in LivaNova PLC (NASDAQ:LIVN)

Charles Schwab Investment Management Inc. increased its position in LivaNova PLC (NASDAQ:LIVN) by 17.7% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 621,959 shares of the company’s stock after buying an additional 93,311 shares during the quarter. Charles Schwab Investment Management Inc. owned about 1.15% of LivaNova worth $32,678,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also made changes to their positions in LIVN. Point72 Asset Management L.P. raised its position in shares of LivaNova by 204.3% in the 2nd quarter. Point72 Asset Management L.P. now owns 1,285,636 shares of the company’s stock worth $70,479,000 after buying an additional 863,157 shares during the period. First Light Asset Management LLC raised its position in shares of LivaNova by 591.1% in the 2nd quarter. First Light Asset Management LLC now owns 710,390 shares of the company’s stock worth $38,944,000 after buying an additional 607,598 shares during the period. Great Lakes Advisors LLC purchased a new position in shares of LivaNova in the 2nd quarter worth $16,614,000. Driehaus Capital Management LLC raised its position in shares of LivaNova by 64.7% in the 2nd quarter. Driehaus Capital Management LLC now owns 544,042 shares of the company’s stock worth $29,824,000 after buying an additional 213,749 shares during the period. Finally, Perceptive Advisors LLC raised its position in shares of LivaNova by 48.5% in the 2nd quarter. Perceptive Advisors LLC now owns 444,000 shares of the company’s stock worth $24,340,000 after buying an additional 145,000 shares during the period. 97.64% of the stock is owned by hedge funds and other institutional investors.

LivaNova Stock Down 1.3 %

Shares of LivaNova stock opened at $51.62 on Wednesday. The business has a 50-day moving average of $52.29 and a 200-day moving average of $51.95. The company has a debt-to-equity ratio of 0.46, a current ratio of 3.37 and a quick ratio of 2.87. The company has a market capitalization of $2.80 billion, a PE ratio of 122.90 and a beta of 0.98. LivaNova PLC has a 1-year low of $42.75 and a 1-year high of $64.47.

Analysts Set New Price Targets

LIVN has been the topic of several research reports. Baird R W raised LivaNova from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, September 17th. The Goldman Sachs Group initiated coverage on LivaNova in a report on Friday, October 4th. They issued a “buy” rating and a $65.00 price target for the company. Needham & Company LLC reiterated a “buy” rating and issued a $75.00 price target on shares of LivaNova in a report on Monday, November 25th. Mizuho lowered their price target on LivaNova from $80.00 to $70.00 and set an “outperform” rating for the company in a report on Thursday, October 31st. Finally, Robert W. Baird increased their price target on LivaNova from $66.00 to $72.00 and gave the company an “outperform” rating in a report on Thursday, October 31st. One research analyst has rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus price target of $69.17.

LivaNova Company Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.